Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Market Analysis & Valuation

UpdatedJul 01, 2026
DataAggregated Company Financials
Companies204
  • 7D1.8%
  • 3M8.2%
  • 1Y16.6%
  • YTD6.6%

The market has climbed 2.2% in the last 7 days, lead by the Healthcare sector with a gain of 5.4%. The market is up 17% over the last 12 months. As for the next few years, earnings are expected to grow by 11% per annum.

Market Valuation and Performance

Has the Swiss Market valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 01 Jul 2026CHF 2.1tCHF 780.9bCHF 105.0b20.5x20x2.7x
Fri, 29 May 2026CHF 2.0tCHF 772.9bCHF 103.7b20.5x19.5x2.6x
Sun, 26 Apr 2026CHF 2.0tCHF 780.0bCHF 109.9b20.2x18x2.5x
Tue, 24 Mar 2026CHF 1.9tCHF 779.3bCHF 109.4b19.8x17x2.4x
Thu, 19 Feb 2026CHF 2.1tCHF 789.7bCHF 117.6b20.5x17.5x2.6x
Sat, 17 Jan 2026CHF 2.0tCHF 800.0bCHF 115.2b20.7x17.6x2.5x
Mon, 15 Dec 2025CHF 1.9tCHF 798.4bCHF 114.4b19.7x16.9x2.4x
Wed, 12 Nov 2025CHF 1.9tCHF 801.7bCHF 114.1b19.1x16.8x2.4x
Fri, 10 Oct 2025CHF 1.9tCHF 777.3bCHF 90.7b19.7x21x2.5x
Sun, 07 Sep 2025CHF 1.9tCHF 774.7bCHF 90.1b19.5x20.8x2.4x
Tue, 05 Aug 2025CHF 1.8tCHF 775.5bCHF 89.9b20.6x20.2x2.3x
Thu, 03 Jul 2025CHF 1.8tCHF 783.1bCHF 106.5b20.2x17x2.3x
Sat, 31 May 2025CHF 1.8tCHF 785.7bCHF 106.4b20.1x17.2x2.3x
Mon, 28 Apr 2025CHF 1.8tCHF 837.2bCHF 157.2b19x11.2x2.1x
Wed, 26 Mar 2025CHF 1.9tCHF 849.9bCHF 158.9b20.1x12x2.2x
Fri, 21 Feb 2025CHF 1.9tCHF 820.1bCHF 116.5b21.5x16.3x2.3x
Sun, 19 Jan 2025CHF 1.8tCHF 819.7bCHF 118.0b21.1x15.2x2.2x
Tue, 17 Dec 2024CHF 1.7tCHF 813.5bCHF 117.3b20.5x14.9x2.1x
Thu, 14 Nov 2024CHF 1.7tCHF 815.8bCHF 117.6b19.8x14.8x2.1x
Sat, 12 Oct 2024CHF 1.8tCHF 803.6bCHF 114.1b21.5x16x2.3x
Mon, 09 Sep 2024CHF 1.8tCHF 799.7bCHF 113.5b21.1x15.7x2.2x
Wed, 07 Aug 2024CHF 1.7tCHF 796.6bCHF 135.5b21.5x12.8x2.2x
Fri, 05 Jul 2024CHF 1.8tCHF 802.6bCHF 125.8b21.5x14.4x2.3x
Sun, 02 Jun 2024CHF 1.8tCHF 803.7bCHF 126.0b22x14.3x2.2x
Tue, 30 Apr 2024CHF 1.7tCHF 799.2bCHF 125.4b21.5x13.7x2.2x
Thu, 28 Mar 2024CHF 1.8tCHF 768.3bCHF 98.5b21.7x18.1x2.3x
Sat, 24 Feb 2024CHF 1.7tCHF 766.1bCHF 111.1b20.3x15.6x2.3x
Mon, 22 Jan 2024CHF 1.7tCHF 766.5bCHF 110.4b18x15.1x2.2x
Wed, 20 Dec 2023CHF 1.7tCHF 764.9bCHF 110.1b18.5x15.3x2.2x
Fri, 17 Nov 2023CHF 1.6tCHF 773.0bCHF 111.5b17.7x14.5x2.1x
Sun, 15 Oct 2023CHF 1.6tCHF 761.3bCHF 100.3b18.1x16.3x2.1x
Tue, 12 Sep 2023CHF 1.7tCHF 750.2bCHF 99.2b18.5x16.8x2.2x
Thu, 10 Aug 2023CHF 1.7tCHF 743.3bCHF 75.3b18.9x22.2x2.3x
Sat, 08 Jul 2023CHF 1.7tCHF 755.6bCHF 76.7b18.9x21.8x2.2x
Price to Earnings Ratio

21.8x


Total Market Cap: CHF 1.7tTotal Earnings: CHF 76.7bTotal Revenue: CHF 755.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Market Price to Earnings3Y Average 16.7x202420252026
Current Market PE
  • Investors are optimistic on the Swiss market, and appear confident in strong long term growth rates.
  • The market is trading at a PE ratio of 20.1x which is higher than its 3-year average PE of 16.7x.
Past Earnings Growth
  • The earnings for Swiss listed companies have grown 11% per year over the last three years, while revenues have remained steady.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Sector Trends

Which sectors have driven the changes within the Swiss Market?

CH Market1.83%
Consumer Discretionary3.78%
Healthcare2.93%
Consumer Staples2.89%
Industrials1.76%
Financials0.46%
Materials0.35%
Real Estate-0.10%
Utilities-0.84%
Telecom-2.22%
Tech-3.64%
Sector PE
  • Investors favour the Tech sector the most for future growth, which is trading above its 3-year average PE ratio of 27.6x.
    • The market's confidence is likely because analysts are expecting annual earnings growth of 21.5% which is higher than its past year's earnings decline of 14.4% per year.
  • The Financials sector is the least preferred by investors for future growth. Although, investor sentiment seems to have improved given that it's trading above its 3-year average of 7.1x.
Forecasted Growth
  • Analysts are most optimistic on the Tech sector, expecting annual earnings growth of 21% over the next 5 years.
  • This is better than its past earnings decline of 14% per year.
  • In contrast, the Real Estate sector is expected to see its earnings decline by 7.1% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuationSector
NESN NestléCHF 83.083.6%
+CHF 7.4b		5.0%PE23.7xConsumer Staples
ROP Roche HoldingCHF 332.802.3%
+CHF 6.0b		27.7%PE20.6xHealthcare
NOVN NovartisCHF 126.582.6%
+CHF 5.8b		29.3%PE21.2xHealthcare
CFR Compagnie Financière RichemontCHF 186.554.6%
+CHF 4.8b		24.5%PE34.3xConsumer Discretionary
ABBN ABBCHF 87.581.7%
+CHF 2.7b		87.6%PE40.4xIndustrials
See more

Market Insights

Header cover image
Yield measures a moment. A decade of raising it measures the business: durable earnings, a clean balance sheet, and management disciplined enough to keep it.
Continue reading
Watt's left in the overcrowded power trade?

Latest News

ROP
CHF 332.80
Roche Holding
7D
2.3%
1Y
27.7%
AMRZ
CHF 42.82
Amrize
7D
-1.1%
1Y
9.4%
UBSG
CHF 40.06
UBS Group
7D
-2.0%
1Y
50.4%
UHR
CHF 197.60
Swatch Group
7D
-3.3%
1Y
53.8%
SCMN
CHF 623.50
Swisscom
7D
-2.3%
1Y
10.2%
Narrative Update • Jun 26

SCMN: Italian And Swiss Market Pressures Will Constrain Upside Potential

Analysts have trimmed their Swisscom price expectations to CHF 600, with mixed views on Swiss and Italian market challenges reflected in a lower Street target alongside a higher internal fair value estimate of CHF 562.82. Analyst Commentary Recent commentary on Swisscom shows a clear split, with some bearish analysts arguing that current pricing already reflects the company’s execution and market position, while others still see room for the valuation to support a higher fair value.
NOVN
CHF 126.58
Novartis
7D
2.6%
1Y
29.3%
Narrative Update • Jun 26

NOVN: Oncology Pipeline Advances Will Drive Future Upside Potential

Analysts have revised their fair value estimate for Novartis to CHF144.47 from CHF138.41, reflecting updated assumptions around revenue growth, the discount rate, and future P/E. What’s in the News for Novartis Novartis agreed to a collaboration with Antares Therapeutics worth up to US$1.9b, including a US$105m upfront payment and potential US$1.8b in milestones, to discover and develop small molecule oncology therapies targeting historically undruggable cancers.
HOLN
CHF 72.88
Holcim
7D
-3.9%
1Y
24.8%
LONN
CHF 545.80
Lonza Group
7D
5.9%
1Y
-3.2%
CFR
CHF 186.55
Compagnie Financière Richemont
7D
4.6%
1Y
24.5%
Analysis Article • Jun 25

Is Now The Time To Look At Buying Compagnie Financière Richemont SA (VTX:CFR)?

Compagnie Financière Richemont SA ( VTX:CFR ) led the SWX gainers with a relatively large price hike in the past couple...
ZURN
CHF 598.60
Zurich Insurance Group
7D
2.4%
1Y
8.0%
Narrative Update • Jun 25

ZURN: Future Returns Will Balance Robotics Insurance Expansion And Cyclical Pricing Pressures

Analysts have modestly lifted the fair value estimate for Zurich Insurance Group to CHF 596.43 from CHF 580.51. This reflects updated assumptions around revenue growth, profit margins and a slightly higher future P/E multiple following recent price target revisions, such as Berenberg's move to CHF 902, along with ongoing neutral views from other firms.
NESN
CHF 83.08
Nestlé
7D
3.6%
1Y
5.0%
Narrative Update • Jun 24

NESN: Gradual Restructuring And Automation Efforts Will Shape 2026 Execution

Analysts have raised their price target on Nestlé by CHF 2 to reflect updated views on the company, citing recent research that points to supportive fundamentals and valuation assumptions that remain broadly unchanged. Analyst Commentary Recent Street research on Nestlé points to a cluster of price target adjustments and a fresh rating, giving investors more context on how experts are thinking about valuation, execution and growth potential for the company.
LISN
CHF 96,000.00
Chocoladefabriken Lindt & Sprüngli
7D
-1.2%
1Y
-27.5%
Narrative Update • Jun 24

LISN: Premium Brand Strength And De Rating Will Support Future Re Rating

Analysts kept the fair value estimate for Chocoladefabriken Lindt & Sprüngli unchanged at CHF 137,000, while recent research points to a more balanced risk reward profile after the stock’s de rating and an updated Street price target of CHF 101,000. What's in the News for Chocoladefabriken Lindt & Sprüngli Chocoladefabriken Lindt & Sprüngli launched Lindt EXCELLENCE Fusion, a premium bar with two distinct layers of dark chocolate on top and smooth milk or white chocolate below, aimed at offering two taste experiences in every bite.
ABBN
CHF 87.58
ABB
7D
1.7%
1Y
87.6%
Narrative Update • Jun 22

ABBN: Automation And Electrification Projects Will Support Measured Long Term Upside

ABB's updated analyst price target implies a move of roughly CHF 5 higher, with analysts pointing to refined fair value estimates, a slightly adjusted discount rate, and modest tweaks to revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on ABB shows a cluster of bullish analysts lifting price targets and, in some cases, upgrading their views.
LOGN
CHF 75.74
Logitech International
7D
-10.7%
1Y
5.0%
HUBN
CHF 223.00
Huber+Suhner
7D
-5.9%
1Y
156.6%
Narrative Update • Jun 18

HUBN: Optical Partnerships And Higher Margins Will Drive Strong Share Upside

Analysts have lifted their price target for Huber+Suhner from CHF 189 to CHF 320, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as key drivers of the change. What’s in the News for Huber+Suhner Huber+Suhner is working with Microsoft’s Azure team in Romsey, UK, to develop and manufacture hollow core fiber (HCF) cable and connector solutions that are already deployed in the Azure network, with higher capacity variants under development.
GALD
CHF 183.90
Galderma Group
7D
4.9%
1Y
59.2%
Narrative Update • Jun 17

GALD: Rising Execution Bar And Rich P/E Will Likely Cap Future Share Upside

Analysts have raised the Galderma Group price target by CHF 5 to CHF 125.65, citing updated assumptions on fair value, revenue growth, profit margins and forward P/E that are consistent with a recent series of target increases from major banks. Analyst Commentary Recent Street research on Galderma Group points to a cluster of higher price targets, framed around updated assumptions for earnings quality, revenue mix and P/E levels.